U.S. stock futures were poised for a second day of gains, following the official announcement of a debt and spending deal by the White House and congressional leaders.Morning Briefread more
Coca-Cola topped Wall Street's expectations for earnings and revenue.Food & Beverageread more
Boris Johnson, one of the biggest voices in the Brexit movement, wins the Conservative Party leadership race by a 2-1 margin.Europe Politicsread more
U.S. stock index futures were higher Tuesday morning after results from major companies topped expectations.US Marketsread more
Iran is pushing boundaries amid rising tensions in the Gulf, but President Trump has so far not been "compelled" to retaliate militarily, analysts say.World Politicsread more
The largest residential brokerage company in the U.S. is partnering with the largest online retailer in a strategy to boost sales for both.Real Estateread more
Two traders say Boeing's on the path to recovery.Trading Nationread more
The Trump administration on Tuesday will propose a rule to tighten food stamp restrictions that would cut about 3.1 million people from the program, U.S. Department of...Politicsread more
Harley Davidson posted its second quarter earnings today, beating analyst expectations on revenue but posting lower sales numbers.Autosread more
Boris Johnson is to be the U.K.'s next prime minister but the charismatic and controversial figure will already divides the party and British public alike.Europe Politicsread more
The deal could be announced as soon as next week, according to the report.Technologyread more
Verily, Alphabet's life sciences arm, has beefed up its advisory board and leadership team as it looks to move beyond research and development and into hospitals and clinics.
The company recently hired Ashraf Hanna, the former CEO of Oric Pharmaceuticals, as its chief operating officer, and brought on Vivian Lee, a radiologist and the former CEO of University of Utah Health, as president of health platforms.
Lee, who left the Utah health system over a controversy related to her firing of an executive, will focus on population health initiatives, furthering the company's interest in managing patient populations.
Verily is starting to more aggressively commercialize its range of services and products, many of which have been in development for more than five years. The company is looking to sell both to pharmaceutical companies and health systems, and is also working with regulators to secure approvals for its products.
"This is not a company with a lack of ambition," said Robert Califf, a former commissioner for the U.S. Food and Drug Administration, who joined the company as an adviser last May. "In health care, there's a lot to be done."
Some of Verily's initiatives, like its device to measure blood using a type of watch, are still in the research phase. But others are further along. In 2016, Verily partnered with Sanofi on a joint venture called Onduo, which is focused on diabetes management.
Verily has also beefed up its scientific advisory board, adding Linda Avey, the co-founder of 23andMe, as well as former Medicare chief Andy Slavitt, former national coordinator for Health Information Technology Karen DeSalvo, and Kathy Giusti, founder of the Multiple Myeloma Research Foundation.
"In the early days, we were very science-oriented so our advisory board spent much of their time reviewing science projects," said Califf. "But now, where we're headed is to delivery, the pragmatic real-world stuff, and we needed a different kind of board."
Both Slavitt and DeSalvo said they are specifically interested in helping Americans with significant medical and social challenges, and not just the healthy and wealthy.
"Technology brings great opportunity to reach hard to reach populations, such as those in rural America," DeSalvo said. It can help "close the disparity gaps."